Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article in Forbes on mental and behavioral healthcare included a contributor article from The American Journal of Managed Care® (AJMC®). The contributor piece, “Mental Health Fraud Exacts High Human and Financial Costs,” reported that the United States loses approximately $100 billion to healthcare fraud annually. Additionally, up to $20 billion are due to fraudulent practices in the mental healthcare sector.
Newsmax’s article on suicide rates among children highlighted an article from AJMC®. The article, “Racial Disparities Seen for Black Children Age 5-12 in Youth Suicide,” reported on a study that found suicide rates for black children between the ages of 5 and 12 were roughly 2 times higher than those of similarly aged white children. Traditionally, suicide rates in the United States have been higher among whites than blacks.
The National Pharmaceutical Council (NPC)’s Tuesday and Wednesday CER Daily Newsfeed included AJMC®’s coverage from the International Society of Pharmacoeconomics Outcomes Research (ISPOR) 23rd Annual International Meeting, held May 19-23 in Baltimore, Maryland. The article, “Transforming Healthcare: Boosting Real-World Evidence With Digital Health,” covered a plenary session at the conference that discussed how digital progress can influence real-world evidence to allow near real-time data analysis and inclusion of specific patient information, lowering costs and providing higher quality care downstream. The article, “Value Assessments in the Age of Personalized Medicine May Require a Cultural Shift, Panel Says,” covered a session where stakeholders grappled with the role of value assessment in a healthcare landscape increasingly focused on the use of precision medicine.
The NPC newsfeeds also included the ISPOR article, “Panelists Give Payer, Patient, and Economist Perspectives on High-Cost Drugs for Rare Diseases,” which addressed the question of how to define value in the always evolving and ever more expensive treatment landscape, as well as AJMC®’s interview with Adrian Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine. In the interview, Hernandez highlights the use of real-world evidence and current barriers.
Thursday’s CER Daily Newsfeed included the article, “BBCIC Seeks to Provide Stakeholders With Real-World Data on Biosimilars,” from AJMC®’s The Center for Biosimilars® . The article reported that during ISPOR, members of the Biologics and Biosimilars Collective Intelligence Consortium discussed ways in which their organization is working to provide real-world evidence on these products to stakeholders.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More